Occudo Quantitative Strategies LP Editas Medicine, Inc. Transaction History

Occudo Quantitative Strategies LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $100,340 - $134,995	14,500 New	14,500 $113,000
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $138,271 - $220,824	-11,371 Reduced 18.35%	50,588 $619,000
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $618,970 - $1.32 Million	61,959 New	61,959 $733,000
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $130,592 - $256,268	-9,275 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $246,251 - $376,286	9,275 New	9,275 $246,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.